Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity

Journal of Vascular and Interventional Radiology

Volumn 25, Issue 7, 2014, Pages 1067-1073

  Padia, Siddharth A ^a   Kwan, Sharon W ^a   Roudsari, Bahman ^a   Monsky, Wayne L ^a   Coveler, Andrew ^b   Harris, William P ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; MICROSPHERE Y 90; UNCLASSIFIED DRUG; YTTRIUM 90; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL ARTICLE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MODERATE HEPATIC IMPAIRMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TUMOR RECURRENCE; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; RADIATION DOSE; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 84903277354     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2014.03.030     Document Type: Article

References (26)

1. A.B. Benson, T.A. Abrams, and E. Ben-Josef et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers J Natl Compr Canc Netw 7 2009 350 391
2. R. Salem, R.J. Lewandowski, and M.F. Mulcahy et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
3. B. Sangro, L. Carpanese, and R. Cianni et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation Hepatology 54 2011 868 878
4. V. Mazzaferro, C. Sposito, and S. Bhoori et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study Hepatology 57 2013 1826 1837
5. A. Riaz, V.L. Gates, and B. Atassi et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization Int J Radiat Oncol Biol Phys 79 2011 163 171
6. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
7. R. Salem, and K.G. Thurston Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies J Vasc Interv Radiol 17 2006 1251 1278
8. R. Salem, and K.G. Thurston Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies J Vasc Interv Radiol 17 2006 1425 1439
9. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. NIH Publication No. 09-7473. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services; 2009.
10. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
11. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
12. J. Bruix, M. Sherman, and J.M. Llovet et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
13. R. Salem, R.J. Lewandowski, and V.L. Gates et al. Research reporting standards for radioembolization of hepatic malignancies J Vasc Interv Radiol 22 2011 265 278
14. E. Garin, L. Lenoir, and Y. Rolland et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results J Nucl Med 53 2012 255 263
15. J.Y. Young, T.K. Rhee, and B. Atassi et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma J Vasc Interv Radiol 18 2007 1375 1382
16. W.Y. Lau, A.S. Kennedy, and Y.H. Kim et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres Int J Radiat Oncol Biol Phys 82 2012 401 407
17. K. Malagari, M. Pomoni, and A. Kelekis et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2009 541 551
18. K. Takayasu, Y. Muramatsu, and T. Maeda et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates AJR Am J Roentgenol 176 2001 681 688
19. K. Hayashi, H. Ina, M. Tezuka, Y. Okada, and T. Irie Local therapeutic results of computed tomography-guided transcatheter arterial chemoembolization for hepatocellular carcinoma: results of 265 tumors in 79 patients Cardiovasc Intervent Radiol 30 2007 1144 1155
20. K. Malagari, M. Pomoni, and H. Moschouris et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis Cardiovasc Intervent Radiol 35 2012 1119 1128
21. R. Golfieri, M. Renzulli, and C. Mosconi et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol 24 2013 509 517
22. B. Jin, D. Wang, and R.J. Lewandowski et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma AJR Am J Roentgenol 196 2011 919 928
23. S.W. Kwan, N. Fidelman, E. Ma, R.K. Kerlan, and F.Y. Yao Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation Liver Transpl 18 2012 727 736
24. M.C. Chern, V.P. Chuang, C.T. Liang, Z.H. Lin, and T.M. Kuo Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors J Vasc Interv Radiol 25 2014 32 40
25. S.P. Kalva, M. Pectasides, and R. Liu et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma Cardiovasc Intervent Radiol 37 2013 381 387
26. S.A. Padia, A. Alessio, S.W. Kwan, D.H. Lewis, S. Vaidya, and S. Minoshima Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis J Vasc Interv Radiol 24 2013 1147 1153